NCT05557591进行中（未招募）2 期
A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 51
- 试验地点
- 104
- 主要终点
- Objective response rate (ORR) as assessed by blinded independent review committee (BIRC) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
研究概览
简要总结
This study is researching an investigational drug, called BNT116, in combination with cemiplimab. BNT116 and cemiplimab will each be called a "study drug", and together be called "study drugs". The study is focused on patients who have advanced non-small cell lung cancer (NSCLC).
The aims of this study are to see how safe and tolerable BNT116 is in combination with cemiplimab and to see how effective BNT116 in combination with cemiplimab is compared to cemiplimab by itself at treating cancer.
The study is looking at several other research questions, including:
- What side effects may happen from receiving the study drugs
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug(s) (which could make the drug less effective or could lead to side effects)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants with non-squamous or squamous histology NSCLC with stage IIIB or stage IIIC disease who are not candidates for surgical resection or definitive chemoradiation per investigator assessment or stage IV (metastatic) disease who received no prior systemic treatment for recurrent or metastatic NSCLC
- •Availability of an archival or on-study obtained formalin-fixed, paraffin-embedded tumor tissue sample as defined in the protocol.
- •Expression of Programmed cell death ligand-1 (PD-L1) ≥50%, as described in the protocol.
- •Participants must have at least 1 radiographically measurable lesion by computerized tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) criteria
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤1
排除标准
- •Participants who have never smoked, defined as smoking ≤100 cigarettes in a lifetime
- •Active or untreated brain metastases or spinal cord compression. Participants are eligible if central nervous system (CNS) metastases are adequately treated and patients have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to enrollment
- •Participants with tumors tested positive for epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene translocations, or C-ros oncogene receptor tyrosine kinase 1 (ROS1) fusions
- •Encephalitis, meningitis, or uncontrolled seizures in the year prior to enrollment
- •Participants with history of interstitial lung disease (eg, idiopathic pulmonary fibrosis or organizing pneumonia), of active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management, or of pneumonitis within the last 5 years
- •Prior splenectomy
- •Uncontrolled infection with human immunodeficiency virus (HIV), HBV or hepatitis C infection (HCV); or diagnosis of immunodeficiency as defined in the protocol
- •Ongoing or recent (within 2 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk of immune-related treatment-emergent adverse events (imTEAEs)
- •Participants requiring corticosteroid therapy (>5 mg prednisone/day or equivalent) within 14 days of randomization
- •Another malignancy that is progressing or requires treatment, except for non melanomatous skin cancer that has undergone potentially curative therapy, in situ cervical carcinoma, or any other localized tumor that has been treated, and the participant is deemed to be in complete remission for at least 2 years prior to enrollment, and no additional therapy is required during the study period
- •Documented or suspected ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection as defined in the protocol
- •Patients who have received prior systemic therapies for NSCLC are excluded except for of the following:
- •Adjuvant or neoadjuvant platinum-based doublet chemotherapy (after surgery and/or radiation therapy) if recurrent or metastatic disease develops more than 6 months after completing therapy if toxicities have resolved to CTCAE grade ≤1 or baseline except for alopecia and peripheral neuropathy.
- •Anti-PD-(L)1 with or without LAG-3 as an adjuvant or neoadjuvant therapy as long as the last dose is >12 months prior to enrollment.
- •Prior exposure to other immunomodulatory or vaccine therapies as an adjuvant or neoadjuvant therapy such as anti-cytotoxic T lymphocyte-associated antigen (anti-CTLA-4) antibodies if the last dose is >6 months prior to enrollment
- •History or current evidence of significant cardiovascular disease including, myocarditis, congestive heart failure (as defined by New York Heart Association Functional Classification III and IV), unstable angina, serious uncontrolled arrhythmia, and myocardial infarction 6 months prior to study enrollment.
- •Hypersensitivity to cemiplimab or BNT116 or any of their excipients, or contraindicated to cemiplimab per approved local labeling.
- •Patients treated with immunostimulatory agents that may influence the efficacy of the investigational medicinal products (IMPs) are not allowed if they received such agents within 6 weeks or five halve lives of the drug.
- •Note: Other protocol-defined Inclusion/Exclusion criteria apply
研究组 & 干预措施
Phase 2: BNT116 + Cemiplimab
Experimental
Arm B: BNT116 is administered by IV injection. Cemiplimab is administered by IV infusion Q3W.
干预措施: BNT116 (Drug)
Phase 2: Cemiplimab
Experimental
Arm A: Cemiplimab is administered by IV infusion Q3W
干预措施: Cemiplimab (Drug)
Phase 2: BNT116 + Cemiplimab
Experimental
Arm B: BNT116 is administered by IV injection. Cemiplimab is administered by IV infusion Q3W.
干预措施: Cemiplimab (Drug)
结局指标
主要结局
Objective response rate (ORR) as assessed by blinded independent review committee (BIRC) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
时间窗: Up to 136 weeks from randomization
Proportion of patients with a best overall response of confirmed complete response (CR) or partial response (PR)
次要结局
- Duration of Response (DOR) as assessed by BIRC using RECIST 1.1(Up to 3 years from last patient randomized)
- DOR by investigator assessment(Up to 3 years from last patient randomized)
- Progression Free Survival (PFS) as assessed by BIRC using RECIST 1.1(Up to 3 years from last patient randomized)
- ORR by investigator assessment(Up to 136 weeks from randomization)
- Incidence of treatment-emergent adverse events (TEAEs)(Up to 3 years)
- PFS by investigator assessment(Up to 3 years from last patient randomized)
- Overall Survival (OS)(Up to 3 years from last patient randomized)
- Incidences of serious adverse events (SAEs)(Up to 3 years)
- Incidences of laboratory abnormalities(Up to 3 years)
- Incidences of deaths(Up to 3 years)
研究者
研究点 (104)
Loading locations...
相似试验
已完成
2 期
Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line ChemotherapyCervical CancerNCT04646005Regeneron Pharmaceuticals113
进行中（未招募）
1 期
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung Cancer (NSCLC)NCT06162572Servier Bio-Innovation LLC102
招募中
1 期
Safety and Efficacy of Intravenous Cemiplimab Plus BNT116 Versus Cemiplimab Alone in Advanced Non-Small Cell Lung Cancer in Adult Participants With PD-L1 = 50%Advanced Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2023-503221-19-00Regeneron Pharmaceuticals Inc.100
进行中（未招募）
2 期
A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPCSquamous Cell Carcinoma of the OropharynxNCT04398524ISA Pharmaceuticals65
已完成
2 期
A Phase 2 Study of Cemiplimab, an Anti-PD-1 Monoclonal Antibody, and ISA101b Vaccine in Patients with Recurrent/Metastatic HPV16 Cervical Cancer who have Experienced Disease Progression after First Line Chemotherapycervical cancerNL-OMON54112Regeneron Pharmaceuticals, Inc.10